Caribou Biosciences (CRBU) EBITDA Margin (2020 - 2026)
Caribou Biosciences' (CRBU) quarterly EBITDA Margin came in at 1096.37% in Q1 2026, up 72739.0% year-on-year from N/an in Q1 2025, and down 51.86% on a QoQ basis from 721.97% in Q4 2025.
Caribou Biosciences (CRBU) EBITDA Margin (2020 - 2026) Analysis & Trends
Caribou Biosciences (CRBU) has 7 years of EBITDA Margin data on file, last reported at 1096.37% in Q1 2026.
- On a quarterly basis, EBITDA Margin rose 72739.0% year-over-year to 1096.37% in Q1 2026; TTM through Mar 2026 was 1175.68%, a 47311.0% increase from a year earlier, with the FY2025 full-year figure at 1329.37%, up 33779.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 1096.37%, down from 721.97% in the prior quarter.
- Over the last five years, EBITDA Margin for CRBU reached as high as 61.84% in Q3 2023 and fell as low as 1893.87% in Q1 2024.
- Historically, EBITDA Margin has averaged 1155.58% across 5 years, with a median of 1052.33% in 2023.
- Across the five-year window, EBITDA Margin sank 182739 bps in 2024 and soared 114972 bps in 2025, its largest moves.
- Year by year, EBITDA Margin stood at 828.22% in 2022, then retreated by 27 bps to 1052.33% in 2023, then plunged by 78 bps to 1871.69% in 2024, then surged by 61 bps to 721.97% in 2025, then tumbled by 52 bps to 1096.37% in 2026.
- Per Business Quant data, the three most recent EBITDA Margin figures were 1096.37% in Q1 2026, 721.97% in Q4 2025, and 1337.58% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Caribou Biosciences | 156.25 Mn | 38.63 Mn | - | -1,096.37% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,096.37% |
| Dec 31, 2025 | -721.97% |
| Sep 30, 2025 | -1,337.58% |
| Jun 30, 2025 | -1,783.95% |
| Mar 31, 2025 | -1,823.76% |
| Dec 31, 2024 | -1,871.69% |
| Sep 30, 2024 | -1,889.23% |
| Jun 30, 2024 | -1,255.80% |
| Mar 31, 2024 | -1,893.87% |
| Dec 31, 2023 | -1,052.33% |
| Sep 30, 2023 | -61.84% |
| Jun 30, 2023 | -875.31% |
| Mar 31, 2023 | -888.52% |
| Dec 31, 2022 | -828.22% |
| Sep 30, 2022 | -803.42% |
| Jun 30, 2022 | -678.22% |
| Mar 31, 2022 | -782.77% |
| Dec 31, 2021 | -797.38% |
| Sep 30, 2021 | -468.09% |
| Jun 30, 2021 | -1,081.57% |